FDA, Eli Lilly

Eli Lilly asks to join FDA in opposing lawsuit from pharmacies
CNBC's Becky Quick reports on news from Eli Lilly. US surgeon general urges cancer warnings for alcoholic drinks 14 Trader Joe's Items That Have Gained a Cult Following for a Good Reason
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow | After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound,
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
Lilly Battles FDA Decision Over Compound Pharmacy Lawsuit
Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs Zepbound and Mounjaro. The lawsuit, filed by compounding pharmacies, aims to reverse the FDA's determination that these drugs are no longer in short supply.
Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know
Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Eli Lilly (NYSE:LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that weight-loss and diabetes drugs such as Lilly's (NYSE:LLY) tirzepatide are no longer in short supply.
Hosted on MSN3d
Lilly's Zepbound approved by FDA for sleep apnea treatment
The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...
FiercePharma2d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Hosted on MSN9h
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...
FiercePharma6d
2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugs
Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...
24/7 Wall St2d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
JD Supra2d
FDA Announced Removal of Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...
MM&M3d
Policy priorities 2025: The biggest health policy issues to look out for next year
From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers, drug-pricing reform may be near the top.